Glucagon-like peptide-1 (GLP-1) receptor agonists have become cornerstone therapies in the management of type 2 diabetes and obesity. Medications such as semaglutide, liraglutide, dulaglutide, and tirzepatide (which also targets GIP receptors) offer significant benefits in glycemic control and weight reduction. However, like all pharmacotherapies, they come with potential side effects. While gastrointestinal symptoms such as nausea, vomiting, and diarrhea are well-documented, a persistent cough is a less commonly discussed but clinically meaningful adverse effect that can impact treatment adherence and patient quality of life.

For patients who develop a chronic cough after initiating GLP-1 therapy, the symptom can be distressing and may lead to premature discontinuation of an otherwise effective medication. Understanding the mechanisms, recognizing the clinical presentation, and implementing evidence-based management strategies are essential for clinicians and patients alike. This article provides a comprehensive overview of managing persistent cough associated with GLP-1 receptor agonists, incorporating current evidence and practical recommendations.

Mechanisms Behind GLP-1 Agonist-Induced Cough

The pathophysiology of cough induced by GLP-1 receptor agonists is not fully understood, but several plausible mechanisms have been proposed based on clinical observations and pharmacological properties.

Vagus Nerve Activation

GLP-1 receptors are expressed widely throughout the body, including in the central nervous system and peripheral autonomic pathways. Activation of GLP-1 receptors on vagal afferent neurons may trigger reflex pathways that stimulate the cough center in the medulla oblongata. This mechanism is analogous to how angiotensin-converting enzyme (ACE) inhibitors cause cough through bradykinin accumulation, though the specific pathways differ. The vagus nerve plays a central role in the cough reflex, and heightened vagal tone from GLP-1 receptor agonism could lower the threshold for coughing.

Local Irritation of the Respiratory Tract

Some GLP-1 receptor agonists are administered subcutaneously, but local effects at the injection site are unlikely to explain cough. However, there is evidence that GLP-1 receptors are present in the airway epithelium and smooth muscle. Direct stimulation of these receptors might induce bronchial hyperresponsiveness or irritate sensory nerve endings in the pharynx and larynx. Patients often describe the cough as originating from the throat, suggesting a laryngeal or pharyngeal component.

Gastroesophageal Reflux and Aspiration

GLP-1 receptor agonists delay gastric emptying, which is a known mechanism for their appetite-suppressing effects. This delayed gastric emptying can exacerbate gastroesophageal reflux disease (GERD). Micro-aspiration of gastric contents into the airway is a well-established cause of chronic cough. The combination of slowed gastric motility and relaxation of the lower esophageal sphincter (potentially influenced by GLP-1 signaling) may create a perfect storm for reflux-related cough. This is particularly relevant in patients with obesity, who already have a higher prevalence of GERD.

Immunologic or Inflammatory Mechanisms

Though less well-characterized, there is some speculation that GLP-1 receptor agonists might modulate immune responses in the airway. GLP-1 has anti-inflammatory properties in some tissues, but its effects on airway inflammation are complex. Rare cases of hypersensitivity reactions, including urticaria and angioedema, have been reported with GLP-1 agonists, and cough could be a manifestation of a low-grade hypersensitivity response. However, this remains an area requiring further research.

Epidemiology and Patient Profile

Cough is not among the most common adverse effects listed in prescribing information for GLP-1 receptor agonists, but clinical trials and post-marketing surveillance have identified it as a recognized side effect with variable incidence.

Incidence in Clinical Trials

In the SUSTAIN program for semaglutide, cough was reported in approximately 2–5% of patients, compared to 1–2% with placebo. The LEADER trial for liraglutide similarly noted a slight increase in respiratory symptoms. While these numbers are modest, the absolute number of patients exposed to GLP-1 agonists globally means that thousands of individuals may experience this side effect. Real-world data suggests the incidence may be higher, as clinical trials often exclude patients with significant comorbidities or polypharmacy.

Risk Factors

Certain patient characteristics may predispose individuals to developing cough. Pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD) could increase susceptibility. Patients with underlying GERD are also more likely to experience cough, especially if the medication exacerbates reflux. Additionally, individuals with a history of cough with other medications (such as ACE inhibitors) may be more sensitive to drug-induced cough in general. Female sex and older age have been suggested as potential risk factors, though the data are not robust.

Temporal Pattern

The cough typically emerges within the first few weeks to months of treatment initiation. It may be dose-dependent, with higher doses more likely to provoke symptoms. Some patients experience cough intermittently, while others report a persistent daily cough that can last for months. In many cases, the cough gradually improves over time as the body adapts to the medication, but in others, it persists and necessitates intervention.

Clinical Presentation and Differential Diagnosis

Proper diagnosis of GLP-1 agonist-induced cough requires a thorough clinical evaluation to rule out other common causes of chronic cough. The cough is typically dry, non-productive, and described as a tickling or irritating sensation in the throat. It is often worse at night or after meals, which may point to a reflux component. Patients may also report associated throat clearing, hoarseness, or a sensation of a lump in the throat (globus sensation).

Key Features of GLP-1 Agonist-Induced Cough

  • Dry and non-productive: Little to no phlegm production, though occasional throat clearing may produce scant mucus.
  • Temporal association with medication: Onset after starting GLP-1 therapy or after dose escalation.
  • Absence of infectious symptoms: No fever, rhinorrhea, or systemic illness.
  • Possible postprandial exacerbation: Worse after eating, especially large meals.
  • Normal chest imaging: Chest X-ray or CT scan shows no pulmonary pathology.

Differential Diagnosis

Before attributing cough to GLP-1 agonist therapy, clinicians must exclude other etiologies. Common causes of chronic cough in adults include upper airway cough syndrome (post-nasal drip), asthma (including cough-variant asthma), GERD, eosinophilic bronchitis, and ACE inhibitor use. Less common causes include chronic infections (pertussis, tuberculosis), bronchiectasis, interstitial lung disease, and lung cancer. A careful history, physical examination, and targeted testing (e.g., spirometry, chest imaging, allergy testing) are warranted, especially if the cough is severe or accompanied by red flag symptoms.

Important Note: Cough can also be a symptom of COVID-19 or other respiratory infections. During respiratory illness seasons, testing for SARS-CoV-2, influenza, and other pathogens should be considered, particularly if the cough is new or worsening.

Management Strategies for Persistent Cough

Managing a persistent cough from GLP-1 receptor agonists requires a stepped approach that balances symptom relief with maintaining the benefits of therapy. The following strategies are arranged from least to most invasive, and shared decision-making with the patient is critical at every step.

Dosage Titration and Administration Timing

Optimizing how the medication is taken can often reduce cough severity without compromising efficacy.

Start Low, Go Slow: Many GLP-1 agonists require dose escalation protocols. Patients who develop cough may benefit from a slower titration schedule. For example, extending the duration at the lowest dose by an additional 2–4 weeks before increasing can allow the body more time to adapt. This is particularly relevant for semaglutide and tirzepatide, which have multi-step dose escalation schedules.

Timing Relative to Meals: Taking the medication with or immediately after a meal may help buffer local irritation. For medications administered once weekly, the day and time of injection can be adjusted so that peak drug levels occur during times when the patient can tolerate symptoms better. Some patients find that taking the medication in the evening allows them to sleep through the worst of the cough.

Avoiding Recumbency After Dosing: For patients whose cough is related to GERD, advising them to remain upright for at least 30–60 minutes after administration can reduce reflux episodes. Elevating the head of the bed by 6–8 inches is another useful measure.

Supportive and Symptomatic Measures

Non-pharmacologic and over-the-counter interventions can provide meaningful relief.

  • Throat lozenges and hard candies: Sucking on lozenges stimulates saliva production, which can soothe a dry, irritated throat. Menthol-containing lozenges have a mild anesthetic effect.
  • Humidifiers and steam inhalation: Dry air can worsen cough by drying out the airway mucosa. Using a cool-mist humidifier in the bedroom or inhaling steam from a bowl of hot water can help maintain moisture.
  • Hydration: Drinking warm liquids such as herbal tea with honey can coat the throat and reduce coughing episodes. Honey has mild anti-inflammatory and antimicrobial properties.
  • Avoiding irritants: Cigarette smoke (including secondhand smoke), strong perfumes, and air pollution can exacerbate cough. Patients should avoid these triggers.
  • Dietary modifications: If reflux is a contributing factor, avoiding large meals, spicy foods, caffeine, and alcohol in the evening can reduce postprandial cough.

Pharmacologic Interventions

If supportive measures are insufficient, pharmacologic options may be considered under medical guidance.

Cough Suppressants: Dextromethorphan is the most common over-the-counter cough suppressant. It acts on the cough center in the brainstem. For dry, non-productive cough, it can be effective. Benzonatate, a prescription non-narcotic cough suppressant, works by numbing stretch receptors in the lungs and airways. Both should be used for short durations and under the advice of a healthcare provider.

Throat Anesthetic Sprays: Local anesthetics such as phenol or benzocaine in oral sprays can provide temporary relief for throat irritation. These are generally safe for short-term use but should not be overused.

Anti-Reflux Medications: For patients with suspected GERD-related cough, adding a proton pump inhibitor (PPI) such as omeprazole or a histamine-2 blocker like famotidine can be helpful. These medications reduce gastric acid production and may alleviate reflux symptoms. Prokinetic agents (e.g., metoclopramide) are not recommended due to side effect risks.

Oral Antihistamines: If there is a suspicion of post-nasal drip or allergic component, a second-generation antihistamine (e.g., loratadine, cetirizine) may be tried. These are generally well-tolerated but can cause mild sedation in some patients.

Medication Switching or Discontinuation

When cough persists despite optimization and supportive management, changing the medication may be necessary.

Switching Within the Class: While all GLP-1 receptor agonists can cause cough, individual patients may tolerate one agent better than another. For example, a patient who develops cough on semaglutide may tolerate liraglutide or dulaglutide without issue. The mechanism of cough may be molecule-specific, and cross-reactivity is not guaranteed. However, switching should be done under medical supervision, and a washout period is not usually required.

Switching to Other Drug Classes: If cough persists with multiple GLP-1 agonists, or if the patient is unable to tolerate any agent in the class, alternative therapies for diabetes or obesity should be considered. For type 2 diabetes, SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) offer glycemic benefits and cardiovascular/renal protection without causing cough. DPP-4 inhibitors (e.g., sitagliptin) have a lower incidence of gastrointestinal side effects and can be a reasonable alternative, though they are less potent for weight loss. For primary obesity management, other options include orlistat, phentermine-topiramate, bupropion-naltrexone, and metabolic surgery.

Discontinuation: In rare cases where the cough is severe, debilitating, or accompanied by concerning symptoms, discontinuation of the GLP-1 agonist may be warranted. The cough typically resolves within days to weeks after stopping the medication. Patients should never stop the medication abruptly without consulting their prescriber, as the underlying condition being treated (diabetes or obesity) requires ongoing management.

When to Seek Medical Advice

While many cases of GLP-1 agonist-induced cough are benign and manageable, there are situations that warrant prompt medical evaluation.

Red Flag Symptoms

Patients should be advised to seek immediate medical attention if the cough is accompanied by any of the following:

  • Shortness of breath or difficulty breathing: This could indicate bronchospasm, aspiration, or an allergic reaction.
  • Chest pain or tightness: Especially if it is crushing, pleuritic, or radiates to the arm or jaw.
  • Coughing up blood (hemoptysis): Even a small amount of blood requires investigation.
  • Fever or chills: May indicate a respiratory infection.
  • Hoarseness or stridor: Could indicate laryngeal edema or vocal cord involvement.
  • Signs of anaphylaxis: Swelling of the lips, tongue, or throat; difficulty swallowing; hives; or dizziness.

These symptoms suggest processes beyond simple drug-induced cough and require prompt diagnostic workup, including chest imaging, pulmonary function tests, and possibly referral to a pulmonologist.

Persistent Cough Beyond 8 Weeks

A chronic cough lasting more than 8 weeks warrants a comprehensive evaluation, even in the absence of red flags. Guidelines from the American College of Chest Physicians recommend a systematic approach that includes ruling out common causes (asthma, GERD, upper airway cough syndrome) before attributing the cough to a medication. Chest X-ray is a reasonable initial test, and spirometry with bronchodilator testing can help identify occult asthma.

Impact on Quality of Life

Even without alarming symptoms, a cough that significantly impairs sleep, work productivity, social interactions, or mental health should be addressed proactively. Patients should not suffer in silence. Clinicians should ask specifically about cough at follow-up visits and use validated tools such as the Leicester Cough Questionnaire to assess impact.

Conclusion

Persistent cough is a recognized but manageable side effect of GLP-1 receptor agonist therapy. While the underlying mechanisms involve vagal activation, local irritation, and reflux, a systematic approach to management can help most patients continue treatment successfully. Starting with dose optimization and supportive care, progressing to pharmacologic interventions, and considering medication switching only when necessary allows patients to derive the metabolic benefits of GLP-1 agonists without undue discomfort.

Clinicians should maintain a high index of suspicion for drug-induced cough in patients on GLP-1 therapy who present with a new dry cough, particularly after excluding other common causes. Patient education about the potential for cough, its benign nature in most cases, and the availability of management strategies can reduce anxiety and improve adherence. Shared decision-making, close follow-up, and a willingness to modify the treatment plan are key to optimizing outcomes.

For more detailed information on the pharmacology of GLP-1 receptor agonists, readers may consult the PubMed database for peer-reviewed studies. Clinical practice guidelines from the American Diabetes Association provide evidence-based recommendations for diabetes management. The FDA prescribing information for individual agents lists all reported adverse effects. For chronic cough evaluation, the American College of Chest Physicians publishes comprehensive guidelines, and the Mayo Clinic offers patient-oriented resources on cough management.